RVMD

Business Context and Reporting Period

Company: Revolution Medicines, Inc. (RVMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for RAS-addicted cancers. The company has no products approved for commercial sale and has incurred net operating losses since inception. Key product candidates include daraxonrasib (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291).

Key Financial Metrics

Note: The company reported no product revenue. Operating expenses consist primarily of Research and Development ($394.9M for Q2; $738.9M for YTD) and General and Administrative ($110.2M for Q2; $211.5M for YTD).

Material Changes vs. Prior Period

• Net Loss Expansion: Net loss increased significantly to $644.4 million for the three months ended June 30, 2026, compared to $247.8 million in the same period in 2025. For the six months, the loss grew to $1.1 billion from $461.2 million.
• Operating Expenses: Total operating expenses rose 91% year-over-year for the quarter ($505.1M vs. $264.7M) and 88% for the six-month period ($950.4M vs. $505.5M). This increase was driven by higher clinical trial costs, manufacturing expenses for pre-launch materials, increased headcount, and stock-based compensation.
• Non-Operating Items: A significant non-cash loss of $151.0 million (Q2) and $166.8 million (YTD) was recorded due to the change in fair value of warrant liabilities, driven by an increase in the company's share price. Interest expense also increased due to new debt instruments.
• Liquidity Position: Cash, cash equivalents, and marketable securities increased from $2.0 billion at December 31, 2025, to $3.9 billion at June 30, 2026, following significant capital raises.

Guidance, Outlook, and Material Events

Capital Raises and Financing

• Follow-on Offering: In April 2026, the company completed a public offering of 12.1 million shares at $142.00 per share, raising net proceeds of approximately $1.65 billion.
• Convertible Notes: In April 2026, the company issued $500.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2033, with net proceeds of approximately $487.1 million.
• Royalty Financing: In May 2026, the company received a $250.0 million payment from Royalty Pharma under Tranche 2 of its Royalty Purchase Agreement. The total liability related to the sale of future royalties stands at $548.5 million.
• ATM Program: The company replaced its 2024 ATM program with a new 2026 ATM program allowing for up to $1 billion in sales. Net proceeds of $141.9 million were generated under the new program in the first six months of 2026.

Clinical and Regulatory Developments

• Daraxonrasib (RMC-6236): In May 2026, the company presented positive Phase 3 results (RASolute 302) showing statistically significant improvements in overall survival (13.2 months vs. 6.7 months) and progression-free survival compared to chemotherapy in second-line metastatic pancreatic cancer. The FDA has accepted the New Drug Application (NDA) for review.
• Breakthrough Designations: The company holds Breakthrough Therapy Designations for daraxonrasib, zoldonrasib, and elironrasib in various indications.
• Collaborations: New clinical collaborations were announced with Synnovation, Bristol-Myers Squibb, and others to evaluate combinations with daraxonrasib and zoldonrasib.

Risks and Contingencies

• Profitability: The company expects to continue incurring significant losses for the foreseeable future and may never achieve profitability.
• Warrant Liability: The company has outstanding public and private warrants expiring in December 2026. The fair value of these warrants is marked to market, creating volatility in net income. The company noted it currently meets conditions to redeem public warrants at $0.01 per warrant.
• Regulatory Risk: Despite positive Phase 3 data, there is no guarantee that the FDA or EMA will approve daraxonrasib or other candidates.

Investor Verification Checklist

• Capital Runway: Verify the company's burn rate against the $3.9 billion cash position to confirm the management assertion of funding operations for at least 12 months.
• Warrant Redemption: Monitor the company's decision on redeeming the outstanding warrants (RVMDW) which expire in December 2026, given the current stock price satisfies redemption conditions.
• Regulatory Approval: Track the FDA review timeline for the daraxonrasib NDA for second-line pancreatic cancer, as this is the primary catalyst for future revenue.
• Debt Covenants: Review the terms of the $500M Convertible Notes and the Royalty Pharma agreements for any restrictive covenants or mandatory prepayment triggers.
• Stock-Based Compensation: Assess the impact of the new retirement benefit provisions on future stock-based compensation expenses, which increased significantly in Q1 2026.